EMMA Stock Overview
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Emmaus Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.31 |
| 52 Week High | US$0.60 |
| 52 Week Low | US$0.071 |
| Beta | 1.92 |
| 1 Month Change | -1.59% |
| 3 Month Change | -18.42% |
| 1 Year Change | -16.22% |
| 3 Year Change | -80.75% |
| 5 Year Change | n/a |
| Change since IPO | -96.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMMA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.3% | -2.7% | 0.06% |
| 1Y | -16.2% | -4.9% | -0.7% |
Return vs Industry: EMMA underperformed the US Pharmaceuticals industry which returned -4.9% over the past year.
Return vs Market: EMMA underperformed the US Market which returned -0.7% over the past year.
Price Volatility
| EMMA volatility | |
|---|---|
| EMMA Average Weekly Movement | 14.3% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EMMA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: EMMA's weekly volatility has decreased from 26% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 55 | Yutaka Niihara | https://www.emmausmedical.com |
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug.
Emmaus Life Sciences, Inc. Fundamentals Summary
| EMMA fundamental statistics | |
|---|---|
| Market Cap | US$16.63m |
| Earnings (TTM) | -US$12.61m |
| Revenue (TTM) | US$21.91m |
0.8x
P/S Ratio-1.3x
P/E RatioIs EMMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMMA income statement (TTM) | |
|---|---|
| Revenue | US$21.91m |
| Cost of Revenue | US$2.01m |
| Gross Profit | US$19.90m |
| Other Expenses | US$32.51m |
| Earnings | -US$12.61m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 90.83% |
| Net Profit Margin | -57.56% |
| Debt/Equity Ratio | -83.2% |
How did EMMA perform over the long term?
See historical performance and comparison